We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical company Elan is to raise the wholesale price of its multiple sclerosis treatment Tysabri following its approval by US regulators earlier this week. RTE Business
